Kura Oncology, Inc. News Releases http://ir.kuraoncology.com/ Kura Oncology, Inc. News Releases en Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-closing-public-offering-and-full-0 SAN DIEGO , June 21, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock, Fri, 21 Jun 2019 16:30:00 -0400 Kura Oncology, Inc. News Releases 8811 Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-pricing-100-million-public-offering SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock at a Tue, 18 Jun 2019 23:31:00 -0400 Kura Oncology, Inc. News Releases 8796 Kura Oncology Announces Commencement of Public Offering of Common Stock http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-commencement-public-offering-common-1 SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions, Tue, 18 Jun 2019 16:01:00 -0400 Kura Oncology, Inc. News Releases 8786 Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-positive-phase-2-trial-tipifarnib – Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an ORR of 47% and a clinical benefit rate of 82% – – 50% CR rate and 75% ORR observed in AITL patients Fri, 14 Jun 2019 07:00:00 -0400 Kura Oncology, Inc. News Releases 8776 Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-present-bank-america-merrill-lynch-health-care SAN DIEGO , May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present Wed, 08 May 2019 08:00:00 -0400 Kura Oncology, Inc. News Releases 8751 Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-first-quarter-2019-financial-results-and – Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA and ICML next month – – Data from ongoing Phase 2 trial of tipifarnib in HRAS mutant HNSCC and other Tue, 07 May 2019 16:05:00 -0400 Kura Oncology, Inc. News Releases 8731 Kura Oncology to Report First Quarter 2019 Financial Results http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-report-first-quarter-2019-financial-results SAN DIEGO , April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2019 financial results after the close of U.S. Tue, 30 Apr 2019 07:30:00 -0400 Kura Oncology, Inc. News Releases 8716 Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-identifies-farnesylated-proteins-associated-cxcl12 – Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – – Pre-treatment tumor CXCL12 expression identified as a potential biomarker of clinical benefit in patients Tue, 02 Apr 2019 16:04:00 -0400 Kura Oncology, Inc. News Releases 8701 Kura Oncology to Participate in Two Upcoming Investor Conferences http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-participate-two-upcoming-investor-conferences-2 SAN DIEGO , March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to Wed, 06 Mar 2019 07:30:00 -0500 Kura Oncology, Inc. News Releases 8676 Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-fourth-quarter-and-full-year-2018 – Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway – – Data from three ongoing Phase 2 trials of tipifarnib anticipated this year – – Third drug candidate menin-MLL inhibitor KO-539 poised to enter clinic next quarter – – $179 million in cash, cash equivalents and investments Tue, 05 Mar 2019 16:03:00 -0500 Kura Oncology, Inc. News Releases 8636